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Abstract
We report a case study of a 55-year-old white male with severe persistent refractory corticosteroid-
dependent asthma receiving inhaled combination therapy with fluticasone propionate 500 μg and
salmeterol 50 μg twice-daily in addition to 6-week cycles of oral corticosteroid treatment for the
previous 7 months. The patient was switched to high-dose mometasone furoate delivered via a dry
powder inhaler (660 μg twice-daily) for 6 weeks.
Considerable improvement from baseline in peak expiratory flow, use of rescue medication, and
asthma symptoms of coughing and wheezing was observed. The patient discontinued the oral
corticosteroid after 1 week of high-dose mometasone furoate treatment. Plasma cortisol value at
8 a.m. was 8.4 μg/dL (normal range, 4.3-22.6 μg/dL) at week 6.
Introduction
Inhaled corticosteroids (ICSs) are the standard controller
therapy for management of persistent asthma [1]. The
majority of patients with asthma have mild-to-moderate
disease, which can be controlled with maintenance
therapy using ICS monotherapy. However, approxi-
mately 10% of patients are considered to have severe
disease. These patients are not well controlled despite
high-dose ICS and long-acting b2-agonist (LABA) ther-
apy; some of these patients may even require treatment
with oral corticosteroids (OCS) [2]. Occasionally,
patients dependent on OCS become refractory to
therapy, a condition commonly known as refractory
corticosteroid-dependent asthma (RCDA). RCDA does
not have a simple definition. The condition is character-
ized by the medication requirement for good disease
control or persistent symptoms, asthma exacerbations,
or airway obstruction regardless of high use of medi-
cation. Clinically, such patients may present with large
variations in peak flows, rapid and progressive loss of
lung function, severe but chronic airflow limitation,
wide-ranging amounts of mucus production, and vary-
ing responses to corticosteroids [3]. Severe refractory
asthma, including corticosteroid-dependent asthma,
likely occurs in less than 5% of cases [3]. However,
severe asthma accounts for a substantial proportion of
total costs associated with treatment [4]. RCDA is very
difficult to control; therefore, alternative approaches
are necessary to improve management of patients who
suffer from it. Here, a novel approach of switching a
patient with RCDA on fluticasone propionate (FP) plus
salmeterol (SAL) therapy to high-dose mometasone
furoate delivered via a dry powder inhaler (MF-DPI)
therapy was tested.
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A 55-year-old white male presented with RCDA. The
patient had uncontrolled, severe, OCS-dependent allergic
asthma and had been receiving inhaled combination
therapy with FP 500 μg and SAL 50 μg twice-daily (FPS)
along with OCS treatment in 6-week cycles for the
previous 7 months, in addition to montelukast 10 mg
daily. The FPS therapy was stopped, and the patient was
switched to MF-DPI 660 μg twice-daily for 6 weeks. The
patient continued OCS, montelukast, and as-needed
albuterol therapy. Peak expiratory flow (PEF), coughing
and wheezing, albuterol use, and OCS use were recorded
at initiation (baseline) and at week 6 of MF-DPI 660 μg
twice-daily treatment; plasma cortisol levels at 8 a.m. were
measured at week 6.
After 6-weeks of treatment with MF-DPI 600 μg twice-daily,
clinical improvement was observed when compared with
baseline. PEF increased from 375 L/min to 600 L/min
(Table 1). After 1 week of high-dose MF-DPI treatment, the
patientdiscontinueduseofOCS.Thefrequencyofalbuterol
use decreased from 8 puffs/d to 4 puffs/d (Table 1). Cough
frequency decreased, and wheezing improved from
continuous to no wheezing. After 6 weeks of high-dose
MF-DPI treatment, the plasma cortisol level at 8 a.m.
was still within normal limits (8.4 μg/dL, normal range
4.3-22.6 μg/dL).
The allergy skin prick testing (ASPT) was conducted on
the volar aspect of the forearms, using disposable
hypodermic needles (26 gauge) and commercially avail-
able aeroallergen solutions: pollens (trees, including elm,
maple, oak, 1:20 w/v; grasses, including timothy, sweet
vernal, bermuda, 10,000 BAU/mL; weeds, including
ragweed, cocklebur, sheep sorrel, 1:20 w/v); pet dander
(cat 10,000 BAU/mL, dog 1:10 w/v); dust mites (Derma-
tophagoides pteronyssinus and D. farinae 30,000 AU/mL);
and molds (including Alternaria and Cladosporium,
1:10 w/v). Positive and negative control solutions were
also applied (histamine phosphate 10 mg/mL and
phosphate-buffered saline with 0.4% phenol, respec-
tively). The ASPT was positive to pollen, dust mite,
molds, and cat dander.
Discussion
Other alternative therapies have also been prescribed for
refractory asthma. Immunomodulating drugs such as
inhibitors of tumor necrosis factor-a (etanercept) [5]
and intravenous immunoglobulins [6] have been used
in treating refractory asthma; however, no consistent
improvement in lung function has been demonstrated.
The use of other corticosteroid-sparing drugs, includ-
ing oral gold and methotrexate, has also been
proposed in patients who are resistant to corticoster-
oids, but little therapeutic effect has been demonstrated
and substantial safety concerns exist with these
medications [2].
In this patient with uncontrolled severe asthma, switching
therapy from FPS to high-dose MF-DPI reduced symp-
toms, decreased use of rescue medication, and established
adequate disease control allowing for discontinuation of
OCS therapy. In addition, high-dose MF-DPI did not
suppress the hypothalamic-pituitary-adrenal axis and had
a favorable safety profile.
Conclusion
In conclusion, high-dose MF-DPI was found to be an
effective and safe treatment option for patients with
RCDA who are receiving high-dose FPS and OCS therapy.
The approach of switching patients with RCDA to an
alternate high-dose ICS needs to be investigated in large,
randomized, placebo-controlled trials.
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Week 6 (with MF-DPI
660 µg BID)
PEF, L/min 375 600
Use of albuterol, puffs/d 8 4
8 AM plasma cortisol, µg/dL
* ND 8.4
BID, twice-daily; FPS, fluticasone propionate and salmeterol; MF-DPI,
mometasone furoate delivered via a dry powder inhaler; ND, not
determined; PEF, peak expiratory flow; puffs/d, puffs per day.
*Normal range is 4.3-22.6 µg/dL.
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